04 January 2017
Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that on 3 January 2017 the Company was notified that Gerard Murray, Quantum's Chief Financial Officer Designate, purchased 200,000 Ordinary Shares of 10 pence each in the Company ('Ordinary Shares') at a price of 44.75 pence per Ordinary Share on 3 January 2017. Following this transaction, Gerard Murray holds 200,000 Ordinary Shares representing approximately 0.12% of the issued share capital of the Company.
As announced on 8 December 2016, Gerard will join Quantum on 23 January 2017 from Ardent Hire Solutions Limited, a private equity backed plant hire business, where he has been the CFO since April 2016.
This announcement is made in accordance with Rule 17 of the AIM Rules for Companies.
For further information:
|Quantum Pharma Plc|
|Chris Rigg, CEO and CFO||Tel: +44 (0) 1207 279 404|
|Craig Swinhoe, Group Strategic Projects Director and Company Secretary||www.quantumpharmagroup.com|
|N+1 Singer (NOMAD and Broker)|
|Aubrey Powell /James White/ Sandy Ritchie||Tel: +44 (0) 20 7496 3000|
|Sandy Fraser / Nick Owen / James White||www.n1singer.com|
|Henry Harrison-Topham / Sophie Cowles / Steph Watson||Tel: +44 (0) 20 7466 5000|
Notes to Editors
Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions: Specials, Niche Pharmaceuticals and Medication Adherence, offering a portfolio of innovative and complementary products and services.
Specials comprises three business units (Quantum Pharmaceutical, UL Medicines and Quantum Aseptics Services). This division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products in response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment. The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.
Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products). This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.
Medication Adherence comprises two business units (Biodose® and Biodose Services®). This division provides products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies and provides the Group with exposure to the homecare and supported living sectors of the care pathway, complementing the focus of the remainder of the Group.
For further information, please visit www.quantumpharmagroup.com.
01 February 2017